Therapeutic cancer vaccine targeted to haah (aspartyl-[asparaginyl]-beta-hydroxylase)
AssigneePanacea Pharmaceuticals, Inc.
InventorsBiswajit Biswas, Carl R. Merril, Hossein A. Ghanbari
Life of this patent
Estimating the term…
Abstract
The present invention encompasses a cancer vaccine therapy targeting Aspartyl-[Asparaginyl]-β-hydroxylase (HAAH). The present invention contemplate bacteriophage expressing HAAH peptide fragments and methods for using said bacteriophage in methods of treating cancer.
Claims20
A bacteriophage comprising at least one amino acid sequence native to Aspartyl-[Asparaginyl]-β-hydroxylase.
A nucleic acid construct comprising at least one nucleotide sequence encoding an amino acid sequence native to Aspartyl-[Asparaginyl]-β-hydroxylase and a nucleotide sequence encoding gpD.
A composition comprising nano-particles, wherein the nano-particles further comprise at least one amino acid sequence native to Aspartyl-[Asparaginyl]-β-hydroxylase.
A method for treating cancer comprising the step of providing an immune system stimulating amount of Lambda phage to a patient, wherein the Lambda phage comprise amino acid sequences native to Aspartyl-[Asparaginyl]-β-hydroxylase expressed on their surface.
Dependencies are inferred from the claim text.